CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells

Tan,Shanfeng; Wang,Kai; Sun,Fuguang; Li,Yang; Gao,Yisheng

doi:10.3892/mmr.2018.9152

CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells

Authors:
- Shanfeng Tan
- Kai Wang
- Fuguang Sun
- Yang Li
- Yisheng Gao
View Affiliations

Affiliations: Department of Urology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China
Published online on: June 11, 2018 https://doi.org/10.3892/mmr.2018.9152
Pages: 1305-1310
Copyright: © Tan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemokines have been demonstrated to serve an important role in a variety of diseases, particularly in tumor progression. There have been numerous studies that have reported that T cells serve major roles in tumor progression. However, the function of CXC motif chemokine ligand 9 (CXCL9) in prostate cancer remains unknown. The present study aimed to investigate the role of CXCL9 in prostate cancer. A prostate cancer mouse model was generated by treating C57/BL‑6 and B6.Cg‑Selplgtm1Fur/J mice with 3,2'‑dimethyl 4‑aminobiphenyl (DMAB). Hematoxylin and eosin staining detected the histopathological alterations of mouse prostate tissues. Immunohistochemistry (IHC) staining determined cell proliferation of the mice. Flow cytometry was used to detect the alterations of T cells in C57+DMAB or CXCL9+DMAB mice. Immunofluorescence revealed that there was positive expression of interleukin‑6 (IL‑6) and transforming growth factor (TGF)‑β in the mouse tissues. The survival rates of C57+DMAB and CXCL9+DMAB mice was analyzed. The association of CXCL9 expression and clinical stages was also evaluated. Results revealed that prostate cancer pathology and cell proliferation in CXCL9+DMAB mice were significantly greater compared with the C57+DMAB mice. Compared with C57+DMAB mice, the number of T cells in peripheral blood and spleen of CXCL9+DMAB mice was significantly reduced. IHC demonstrated that the expression of IL‑6 and TGF‑β was significantly downregulated in the CXCL9+DMAB mice. The survival rate of CXCL9+DMAB mice was significantly decreased compared with the C57+DMAB mice. In addition, reverse transcription‑quantitative polymerase chain reaction analysis demonstrated that CXCL9 mRNA expression in clinical samples was positively associated with clinical pathological stages of prostate cancer. In conclusion, CXCL9 may promote prostate cancer progression via inhibition of cytokines from T cells.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, et al: Customized viral immunotherapy for HPV-associated cancer. Cancer Immunol Res. 5:847–859. 2017. View Article : Google Scholar : PubMed/NCBI
3	Dong B, Minze LJ, Xue W and Chen W: Molecular insights into the development of T cell-based immunotherapy for prostate cancer. Expert Rev Clin Immunol. 10:1547–1557. 2014. View Article : Google Scholar : PubMed/NCBI
4	Kumai T, Fan A, Harabuchi Y and Celis E: Cancer immunotherapy: Moving forward with peptide T cell vaccines. Curr Opin Immunol. 47:57–63. 2017. View Article : Google Scholar : PubMed/NCBI
5	Melssen M and Slingluff CL Jr: Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol. 47:85–92. 2017. View Article : Google Scholar : PubMed/NCBI
6	Wang P, Li S, Siriwon N, Zhang X, Yang S, Jin T, He F, Kim YJ, Mac J, Lu Z, Wang S, et al: Enhanced cancer immunotherapy by chimeric antigen receptor-modified T Cells engineered to secrete checkpoint inhibitors. Clin Cancer Res. 23:6982–6992. 2017. View Article : Google Scholar : PubMed/NCBI
7	Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J, Lu K, Rennekamp AJ, Hofmann H, Bates P and Pöhlmann S: Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. Virology. 413:265–274. 2011. View Article : Google Scholar : PubMed/NCBI
8	Gao HM, Zhou H, Zhang F, Wilson BC, Kam W and Hong JS: HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci. 31:1081–1092. 2011. View Article : Google Scholar : PubMed/NCBI
9	Swamydas M, Ricci K, Rego SL and Dréau D: Mesenchymal stem cell-derived CCL-9 and CCL-5 promote mammary tumor cell invasion and the activation of matrix metalloproteinases. Cell Adh Migr. 7:315–324. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kuo P, Tuong ZK, Teoh SM, Frazer IH, Mattarollo S and Leggatt GR: HPV16E7-induced hyperplasia promotes CXCL9/10 expression and induces CXCR3⁺ T-cell migration to skin. J Invest Dermatol. S0022–202X, ppi 33358-4. 2017.
11	Matsumoto M, Oshiumi H and Seya T: Antiviral responses induced by the TLR3 pathway. Rev Med Virol. 21:67–77. 2011. View Article : Google Scholar : PubMed/NCBI
12	Beider K, Abraham M and Peled A: Chemokines and chemokine receptors in stem cell circulation. Front Biosci. 13:6820–6833. 2008. View Article : Google Scholar : PubMed/NCBI
13	Han K, Zhao T, Chen X, Bian N, Yang T, Ma Q, Cai C, Fan Q, Zhou Y and Ma B: microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R. Int J Oncol. 45:1437–1449. 2014. View Article : Google Scholar : PubMed/NCBI
14	Drouillard A, Puleo F, Bachet JB, Ouazzani S, Calomme A, Demetter P, Verset G, Van Laethem JL and Maréchal R: DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer. Br J Cancer. 115:1245–1252. 2016. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Arnatt CK, Adams JL, Zhang Z, Haney KM, Li G and Zhang Y: Design, syntheses, and characterization of piperzine based chemokine receptor CCR5 antagonists as anti prostate cancer agents. Bioorg Med Chem Lett. 24:2319–2323. 2014. View Article : Google Scholar : PubMed/NCBI
17	Aaron M, Klein RD, Rengel RC, Clinton SK, Kulp SK, Kashida Y, Yamaguchi M, Wang X and Chen CS: Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol Pathol. 35:549–561. 2007. View Article : Google Scholar : PubMed/NCBI
18	Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB and Lokeshwar BL: Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 67:6854–6862. 2007. View Article : Google Scholar : PubMed/NCBI
19	Hol J, Wilhelmsen L and Haraldsen G: The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in weibel-palade bodies. J Leukoc Biol. 87:501–508. 2010. View Article : Google Scholar : PubMed/NCBI
20	Corbel SY, Merzaban JS, Carlow DA, Gossens K, Duenas J, So L, Yi L and Ziltener HJ: Recruitment of adult thymic progenitors is regulated by P-selectin and its ligand PSGL-1. Nat Immunol. 6:626–634. 2005. View Article : Google Scholar : PubMed/NCBI
21	Delk NA and Farach-Carson MC: Interleukin-6: A bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells. Autophagy. 8:650–663. 2012. View Article : Google Scholar : PubMed/NCBI
22	Rautava S, Lu L, Nanthakumar NN, Dubert-Ferrandon A and Walker WA: TGF-β2 induces maturation of immature human intestinal epithelial cells and inhibits inflammatory cytokine responses induced via the NF-κB pathway. J Pediatr Gastroenterol Nutr. 54:630–638. 2012. View Article : Google Scholar : PubMed/NCBI
23	Guo R, Meng Q, Guo H, Xiao L, Yang X, Cui Y and Huang Y: TGF-β2 induces epithelial-mesenchymal transition in cultured human lens epithelial cells through activation of the PI3K/Akt/mTOR signaling pathway. Mol Med Rep. 13:1105–1110. 2016. View Article : Google Scholar : PubMed/NCBI
24	Echeverría C, Montorfano I, Tapia P, Riedel C, Cabello-Verrugio C and Simon F: Endotoxin-induced endothelial fibrosis is dependent on expression of transforming growth factors β1 and β2. Infect Immun. 82:3678–3686. 2014. View Article : Google Scholar : PubMed/NCBI
25	Chen H, Sun Y, Wu C, Magyar CE, Li X, Cheng L, Yao JL, Shen S, Osunkoya AO, Liang C and Huang J: Pathogenesis of prostatic small cell caricinma involves the inactivation of the P53 pathway. Endocr Relat Cancer. 19:321–331. 2012. View Article : Google Scholar : PubMed/NCBI
26	Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak TW and Ohashi PS: TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest. 117:3833–3845. 2007.PubMed/NCBI